Patient case: 74-year-old female with melanoma; genetic feature: no tumor infiltrating lymphocytes

Clinical trial: A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Summary: The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with nivolumab in participants with locally advanced or metastatic solid tumors. The study will consist of 2 parts: ABBV-368 dose escalation and ABBV-368 tumor-specific dose expansion (non-small cell lung cancer [NSCLC] cohort and head and neck cancer cohort) .


Eligibility: Inclusion Criteria:
  -  Participants must have histologic or cytology diagnosis of a known immunogenic solid tumor, as described for Part 1 Dose Escalation and Part 2 Cohort Expansion:
  -  Parts 1A and 1B Dose Escalation:
  -  1A: Subjects with advanced or metastatic solid tumors that have exhausted standard treatment for their incurable disease and who may be treatment naïve to a programmed cell death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) targeting agent and for which there is no anti-PD-1/PD-L1 agent approved. Additional tumor types for which there is approved PD-1/PD-L1 therapy may be considered at the Sponsor's discretion provided they have failed such therapy in the past.
  -  1B: Subjects for whom there is approved PD-1/PD-L1 targeting agent who are treatment-naïve to a PD-1/PD-L1 targeting agent; subjects for whom there is currently no PD-1/PD-L1 approved therapy and are diagnosed with immunogenic type tumors (eligible tumor types to be discussed with the sponsor); subjects who have been treated with a PD1/PD-L1 targeting agent and are refractory to such agent.
  -  Part 2A and 2B Cohort Expansion:
  -  Non Small Cell Lung Cancer (NSCLC): Participants with locally advanced or metastatic NSCLC who have failed platinum-based therapy and a PD-1/PD-L1 targeting agent. Participants with known genomic tumor aberrations for which there is approved targeted therapy should have disease progression on these therapies prior to receiving ABBV-368.
  -  Head and Neck cohort: Participants with recurrent squamous cell head and neck carcinoma that are not candidates for curative treatment with local or systemic therapy, or metastatic (disseminated) head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies. Tumor progression or recurrence must have occurred within 6 months of last dose of platinum therapy. Participants must be treatment- naïve to a PD-1/PD-L1 targeting agent.
  -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2.
  -  Subject must have immune-related Response Evaluation Criteria for Solid Tumors (irRECIST) evaluable or measurable disease in the PART 1 and measurable disease per irRECIST in PART 2
  -  Adequate bone marrow, kidney and liver function.
  Exclusion Criteria:
  -  Received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 21 days prior to the first dose of ABBV-368.
  -  Prior treatment with an OX40 targeting agent.
  -  has known uncontrolled metastases to the central nervous system (CNS).
  -  History of or active autoimmune disorders and other conditions that compromise or impair the immune system.
  -  Active bacterial, fungal or viral infection including hepatitis B (HBV) or hepatitis C (HCV).

Relevance to patient case: not relevant